Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency

ABSTRACT Introduction Hereditary angioedema due to C1-inhibitor (C1-INH-HAE) is a rare disease characterized by unpredictable swelling attacks that may be life-threatening when affecting the upper airways. Understanding the pathophysiology of HAE and the mechanism of bradykinin-mediated angioedema allowed the development of new therapies for the treatment of HAE: clinical trials are ongoing to expand the number of drugs available for on-demand treatment and prophylaxis. Areas covered Authors discuss the products that have been used to treat this disease for many years and present the most recently marketed products and those which are under development. Expert opinion Significant therapeutic progress has been made in HAE. In particular, drugs targeting specific molecules involved in the angioedema formation were developed and studies with new drugs are ongoing. In the coming years, more effective therapies with easier administration route options for on-demand treatment and long-term prophylaxis will be available to treat this disease and the variety of patients. Gene therapy strategies may offer a definitive treatment. High costs of current and new drugs may be a limiting factor for their availability, especially in developing countries.

[1]  J. Bernstein,et al.  Inhibition of Prekallikrein for Hereditary Angioedema. , 2022, The New England journal of medicine.

[2]  R. Lockey,et al.  The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update , 2022, The World Allergy Organization journal.

[3]  J. Bernstein,et al.  Long‐term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study , 2021, Allergy.

[4]  J. Bernstein,et al.  Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). , 2021, The journal of allergy and clinical immunology. In practice.

[5]  William H. Yang,et al.  Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial. , 2020, The Journal of allergy and clinical immunology.

[6]  C. Tascini,et al.  Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key? , 2020, Frontiers in Immunology.

[7]  William H. Yang,et al.  Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. , 2019, The journal of allergy and clinical immunology. In practice.

[8]  M. Cicardi,et al.  Current and emerging biologics for the treatment of hereditary angioedema , 2019, Expert opinion on biological therapy.

[9]  William H. Yang,et al.  Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial , 2018, JAMA.

[10]  Meng Chen,et al.  Emerging Therapies in Hereditary Angioedema. , 2017, Immunology and allergy clinics of North America.

[11]  William H. Yang,et al.  Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor , 2017, The New England journal of medicine.

[12]  M. Cicardi,et al.  Current treatment options for hereditary angioedema due to C1 inhibitor deficiency , 2016, Expert opinion on pharmacotherapy.

[13]  M. Riedl Critical appraisal of androgen use in hereditary angioedema: a systematic review. , 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[14]  M. Triggiani,et al.  Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group , 2014, Allergy.

[15]  M. Cicardi,et al.  Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency , 2013, Expert review of clinical immunology.

[16]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[17]  K. Bork,et al.  Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. , 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[18]  M. López-Trascasa,et al.  Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. , 2008, The Journal of allergy and clinical immunology.

[19]  W. Tremaine,et al.  Hereditary angioedema: a broad review for clinicians. , 2001, Archives of internal medicine.